<DOC>
	<DOCNO>NCT01739621</DOCNO>
	<brief_summary>To determine safety efficacy Proellex premenopausal woman uterine fibroid previously complete study ZPV-200 .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Efficacy ProellexÂ® ( Telapristone Acetate ) Administered Vaginally Treatment Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200</brief_title>
	<detailed_description>This open label , extension study ZPV-200 applicable multiple study site . Subjects choose administer 12 mg Proellex vaginal dos twice daily ( morning evening ) . Total study participation ZPV-200 EXT may 120 day drug treatment separate ZPV-200 off-drug interval 30 day follow visit . Subjects already enrol ZPV-200EXT remainder subject enroll option administer 12 mg vaginal capsule twice daily . This choice provide new subject Visit 1 . The first 4 subject chose administer 12 mg Proellex twice daily , additional study procedure baseline visit day . Once subject select dose regimen subject must remain dose remainder study . All subject enter ZPV-200EXT study complete ZPV-200 study complete off-drug interval prior start first dosing cycle . In off-drug interval , subject must menses prior resumption dose cycle luteal phase . Efficacy measurement consist UFS-QOL ( uterine fibroid symptom quality life survey ) sub-scores total score , number bleeding day per drug treatment cycle record subject diary . Fibroid size assess MRI ( magnetic resonance imaging ) end treatment ( Visit 5 ) , change size uterine fibroid compare MRI result Visit 2 Visit 10 ZPV-200 . Safety measurement study include adverse event ( AEs ) , clinical laboratory test , hormone test , physical examination ( include breast examination pelvic examination PAP smear ) vital sign .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Have negative pregnancy test Baseline visit Subject successfully complete ZPV200 demonstrate return menses Women abnormally high liver enzymes liver disease . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) exceed 1.5x upper limit normal ( ULN AND ) total bilirubin exceed 1.5x ULN baseline confirm repeat ) . Clinically significant abnormal finding baseline examination condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>